Economic analysis of intravenous immunoglobulin and plasma exchange therapies for the treatment of Guillain-Barré Syndrome in a university-based hospital in the South of Brazil

Autores

  • Alexandre Paulo Machado de Brito Programa de Pós-Graduação em Epidemiologia:Gestão de Tecnologia em Saúde; Mestrado Profissional
  • Maria Angélica Pires Ferreira Hospital de Clínicas de Porto Alegre
  • Paola Panazzolo Maciel Hospital de Clínicas de Porto Alegre
  • Leila Beltrami Moreira UFRGS

Palavras-chave:

Síndrome de Guillain-Barré

Resumo

Introduction: Direct costs for treating Guillain-Barré Syndrome (GBS) represent a significant financial burden to public hospitals. Few studies compared the cost of plasma exchange (PE) treatment with human intravenous immunoglobulin (IVIg).

Objectives: To compare the cost of two therapies for GBS: IVIg and PE. Secondary objective was to evaluate compliance to IVIg prescription guidelines of the Pharmacy and Therapeutics Committee (PTC).

Methods: A cross-sectional study included 25 patients with GBS admitted in a university affiliated hospital from June, 2003 through June, 2008. The costs of IVIg (n=20) and PE (n=5) were evaluated through the cost minimization method, considering direct medical costs yield by the management of the institution. Patients receiving treatments other than PE or IVIg were excluded. Data were collected by medical records review. Clinical endpoint was disability on discharge, established by the 7-point scale of Hughes. Compliance to the PTC guidelines was evaluated considering the dose and prescription regime of IVIg.

Results: Twenty-five participants, ranging from 2 to 70 years of age, were included. No difference occurred in any medical variables related to the treatment or in the main clinical outcome measured by the Hughes’ scale. The mean direct cost of PE treatment was US$ 6,059± 1,701 per patient, and the same expense for IVIg was US$ 18,344±12,259 (P = 0.035). Total inpatient cost was US$ 25,730± 18,714 in the PE group, and 34,768± 27,766 (p=0.530) in the IVIg group.

Conclusions: In a university-based hospital, PE is equally effective and less expensive than IVIg to treat GBS.

Downloads

Não há dados estatísticos.

Biografia do Autor

Alexandre Paulo Machado de Brito, Programa de Pós-Graduação em Epidemiologia:Gestão de Tecnologia em Saúde; Mestrado Profissional

Mestrado Profissional

Maria Angélica Pires Ferreira, Hospital de Clínicas de Porto Alegre

Comissão de Medicamentos

Paola Panazzolo Maciel, Hospital de Clínicas de Porto Alegre

Comissão de Medicamentos

Leila Beltrami Moreira, UFRGS

Departamento de Farmacologia da UFRGS;

Programa de Pós-Graduação em Epidemiologia:Gestão de Tecnologia em Saúde; Mestrado Profissional

Comissão de Medicamentos do Hospital de Clínicas de Porto Alegre

Downloads

Publicado

2011-10-26

Como Citar

1.
Brito APM de, Ferreira MAP, Maciel PP, Moreira LB. Economic analysis of intravenous immunoglobulin and plasma exchange therapies for the treatment of Guillain-Barré Syndrome in a university-based hospital in the South of Brazil. Clin Biomed Res [Internet]. 26º de outubro de 2011 [citado 29º de junho de 2022];31(3). Disponível em: https://www.seer.ufrgs.br/index.php/hcpa/article/view/19110

Edição

Seção

Artigos Originais